GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » E10

Haemonetics (Haemonetics) E10 : $1.00 (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Haemonetics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Haemonetics's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.400. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $1.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Haemonetics's average E10 Growth Rate was 20.50% per year. During the past 3 years, the average E10 Growth Rate was 13.20% per year. During the past 5 years, the average E10 Growth Rate was 7.30% per year. During the past 10 years, the average E10 Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Haemonetics was 17.20% per year. The lowest was -15.30% per year. And the median was 4.35% per year.

As of today (2024-05-21), Haemonetics's current stock price is $93.19. Haemonetics's E10 for the quarter that ended in Mar. 2024 was $1.00. Haemonetics's Shiller PE Ratio of today is 93.19.

During the past 13 years, the highest Shiller PE Ratio of Haemonetics was 223.42. The lowest was 27.14. And the median was 88.57.


Haemonetics E10 Historical Data

The historical data trend for Haemonetics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics E10 Chart

Haemonetics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.70 0.69 0.66 0.83 1.00

Haemonetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.93 0.95 0.97 1.00

Competitive Comparison of Haemonetics's E10

For the Medical Instruments & Supplies subindustry, Haemonetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Haemonetics's Shiller PE Ratio falls into.



Haemonetics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Haemonetics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.4/131.7762*131.7762
=0.400

Current CPI (Mar. 2024) = 131.7762.

Haemonetics Quarterly Data

per share eps CPI Adj_EPS
201406 -0.070 100.560 -0.092
201409 0.140 100.428 0.184
201412 0.310 99.070 0.412
201503 -0.060 99.621 -0.079
201506 -0.010 100.684 -0.013
201509 0.250 100.392 0.328
201512 -1.170 99.792 -1.545
201603 -0.173 100.470 -0.227
201606 -0.200 101.688 -0.259
201609 0.380 101.861 0.492
201612 0.300 101.863 0.388
201703 -0.984 102.862 -1.261
201706 0.380 103.349 0.485
201709 0.380 104.136 0.481
201712 -0.120 104.011 -0.152
201803 0.220 105.290 0.275
201806 -0.050 106.317 -0.062
201809 0.350 106.507 0.433
201812 0.350 105.998 0.435
201903 0.400 107.251 0.491
201906 -0.170 108.070 -0.207
201909 0.720 108.329 0.876
201912 0.580 108.420 0.705
202003 0.350 108.902 0.424
202006 0.210 108.767 0.254
202009 0.940 109.815 1.128
202012 0.620 109.897 0.743
202103 -0.220 111.754 -0.259
202106 -0.090 114.631 -0.103
202109 0.290 115.734 0.330
202112 0.450 117.630 0.504
202203 0.190 121.301 0.206
202206 0.380 125.017 0.401
202209 0.640 125.227 0.673
202212 0.640 125.222 0.673
202303 0.570 127.348 0.590
202306 0.800 128.729 0.819
202309 0.480 129.860 0.487
202312 0.610 129.419 0.621
202403 0.400 131.776 0.400

Add all the adjusted EPS together and divide 10 will get our e10.


Haemonetics  (NYSE:HAE) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Haemonetics's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=93.19/1
=93.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Haemonetics was 223.42. The lowest was 27.14. And the median was 88.57.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Haemonetics E10 Related Terms

Thank you for viewing the detailed overview of Haemonetics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277